145 related articles for article (PubMed ID: 24766491)
1. Childhood acute lymphoblastic leukemia: 12 years of experience, using a Berlin-Frankfurt-Münster approach, in a Greek center.
Ampatzidou M; Panagiotou JP; Paterakis G; Papadakis V; Papadhimitriou SI; Parcharidou A; Papargyri S; Rigatou E; Avgerinou G; Tsitsikas K; Vasdekis V; Haidas S; Polychronopoulou S
Leuk Lymphoma; 2015 Jan; 56(1):251-5. PubMed ID: 24766491
[No Abstract] [Full Text] [Related]
2. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
3. Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany.
Ritter J; Creutzig U; Reiter A; Riehm H; Schellong G
J Cancer Res Clin Oncol; 1990; 116(1):100-3. PubMed ID: 2179227
[No Abstract] [Full Text] [Related]
4. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
5. Treatment and prognosis of childhood acute lymphoblastic leukemia on protocols ALL-BFM 90, 95 and ALL IC-BFM 2002: a retrospective single-center study from Olomouc, Czech Republic.
Volejnikova J; Jarosova M; Pospisilova D; Novak Z; Vrbkova J; Hajduch M; Mihal V
Neoplasma; 2016; 63(3):456-61. PubMed ID: 26925793
[TBL] [Abstract][Full Text] [Related]
6. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.
Herold R; von Stackelberg A; Hartmann R; Eisenreich B; Henze G
J Clin Oncol; 2004 Feb; 22(3):569-70; author reply 570-1. PubMed ID: 14752084
[No Abstract] [Full Text] [Related]
7. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
8. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Reiter A; Schrappe M; Parwaresch R; Henze G; Müller-Weihrich S; Sauter S; Sykora KW; Ludwig WD; Gadner H; Riehm H
J Clin Oncol; 1995 Feb; 13(2):359-72. PubMed ID: 7844597
[TBL] [Abstract][Full Text] [Related]
10. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M
Leukemia; 2010 Feb; 24(2):265-84. PubMed ID: 20010625
[TBL] [Abstract][Full Text] [Related]
12. ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.
Kocak U; Gursel T; Kaya Z; Aral YZ; Albayrak M; Keskin EY; Belen B; Isık M; Oner N
Pediatr Hematol Oncol; 2012 Mar; 29(2):130-40. PubMed ID: 22376016
[TBL] [Abstract][Full Text] [Related]
13. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.
Reismüller B; Peters C; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Dieckmann K; Gadner H; Attarbaschi A; Mann G;
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e200-4. PubMed ID: 23652878
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome for children with non-high risk acute lymphoblastic leukaemia after using an ALL IC-BFM 2002-based protocol in Shanghai, China.
Gao YJ; Qian XW; Lu FJ; Zhai XW; Wang HS; Li J
Br J Haematol; 2013 Feb; 160(3):363-7. PubMed ID: 23151178
[TBL] [Abstract][Full Text] [Related]
15. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
17. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.
Gaynon PS; Steinherz PG; Bleyer WA; Ablin AR; Albo VC; Finklestein JZ; Grossman NJ; Novak LJ; Pyesmany AF; Reaman GH
J Clin Oncol; 1993 Nov; 11(11):2234-42. PubMed ID: 8229139
[TBL] [Abstract][Full Text] [Related]
18. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
19. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M; Willasch AM; Dalle JH; Wachowiak J; Yaniv I; Ifversen M; Sedlacek P; Guengoer T; Lang P; Bader P; Sufliarska S; Balduzzi A; Strahm B; von Luettichau I; Hoell JI; Borkhardt A; Klingebiel T; Schrappe M; von Stackelberg A; Glogova E; Poetschger U; Meisel R; Peters C
Br J Haematol; 2018 Jan; 180(1):82-89. PubMed ID: 29193007
[TBL] [Abstract][Full Text] [Related]
20. Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia.
Junghanns AS; Wittig S; Woehlecke C; Lehmann T; Arndt C; Gruhn B
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2221-8. PubMed ID: 26224397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
